{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T23:55:17Z","timestamp":1793145317024,"version":"4.5.0"},"reference-count":135,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T00:00:00Z","timestamp":1755561600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Bladder cancer remains a significant global health challenge, particularly affecting male populations. While radical cystectomy and chemotherapy have been mainstays of treatment, their substantial morbidity and impact on quality of life have driven the development of bladder-preserving immunotherapeutic strategies. Clinical trial data support the use of ICIs as first-line therapy for cisplatin-ineligible patients, second-line treatment for platinum-refractory disease, and maintenance therapy. This review comprehensively summarizes the advances in bladder cancer immunotherapy, focusing on the tumor immune microenvironment and emerging treatment modalities, as well as the roles of immune checkpoint inhibitors (ICIs) targeting PD-1\/PD-L1 and CTLA-4 pathways, which have demonstrated remarkable efficacy in both muscle-invasive (MIBC) and non-muscle invasive bladder cancer (NMIBC). This review also provides novel approaches including combination immunotherapies, tumor vaccines, adoptive cellular therapies, and oncolytic viruses. Overall, these immunotherapeutic advances are transforming bladder cancer management, offering improved outcomes while reducing treatment morbidity.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1609871","type":"journal-article","created":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T05:20:03Z","timestamp":1755580803000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Advances in the immunological microenvironment and immunotherapy of bladder cancer"],"prefix":"10.3389","volume":"16","author":[{"given":"Le","family":"Meng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangyu","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuran","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bowen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoxun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoling","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,8,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.18502\/ijaai.v24i4.19132","article-title":"Immune landscape and prognostic significance of gene expression profiles in bladder cancer: insights from immune cell infiltration and risk modeling","volume":"24","author":"Zhou","year":"2025","journal-title":"Iran J Allergy Asthma Immunol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1186\/s13046-025-03464-x","article-title":"Tumor-intrinsic ENO1 inhibition promotes antitumor immune response and facilitates the efficacy of anti-PD-L1 immunotherapy in bladder cancer","volume":"44","author":"Shen","year":"2025","journal-title":"J Exp Clin Cancer Res"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-025-02833-y","article-title":"Efficacy of cisplatin-based neoadjuvant chemotherapy and risk factors for residual extravesical disease in muscle-invasive bladder cancer: insights from a nationwide cohort","author":"Saito","year":"2025","journal-title":"Int J Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.32604\/or.2024.055155","article-title":"Biomarkers for predicting bladder cancer therapy response","volume":"33","author":"Mihai","year":"2025","journal-title":"Oncol Res"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)01188-6","article-title":"Current best practice for bladder cancer: a narrative review of diagnostics and treatments","volume":"400","author":"Comp\u00e9rat","year":"2022","journal-title":"Lancet"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/eji.202048747","article-title":"Combined anti-PD-1 and anti-CTLA-4 checkpoint blockade: treatment of melanoma and immune mechanisms of action","volume":"51","author":"Willsmore","year":"2021","journal-title":"Eur J Immunol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1007\/s12672-025-01769-z","article-title":"Elucidating stearoyl metabolism and NCOA4-mediated ferroptosis in gastric cancer liver metastasis through multi-omics single-cell integrative mendelian analysis: advancing personalized immunotherapy strategies","volume":"16","author":"Yang","year":"2025","journal-title":"Discov Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3390\/cells12121606","article-title":"Recent advances in CAR-based solid tumor immunotherapy","volume":"12","author":"Shin","year":"2023","journal-title":"Cells"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1460308","article-title":"Deciphering the role of tryptophan metabolism-associated genes ECHS1 and ALDH2 in gastric cancer: implications for tumor immunity and personalized therapy","volume":"15","author":"Wang","year":"2024","journal-title":"Front Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.21037\/tcr.2017.06.48","article-title":"The role of the tumor microenvironment in bladder cancer development and progression","volume":"6","author":"Kang","year":"2017","journal-title":"Translational Cancer Research"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00175","article-title":"Modifying the non-muscle invasive bladder cancer immune microenvironment for optimal therapeutic response","volume":"10","author":"Annels","year":"2020","journal-title":"Front Oncol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e70685","DOI":"10.1111\/jcmm.70685","article-title":"The key role of COA6 in pancreatic ductal adenocarcinoma: metabolic reprogramming and regulation of the immune microenvironment","volume":"29","author":"Jiang","year":"2025","journal-title":"J Cell Mol Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.01270","article-title":"Immune responses in bladder cancer-role of immune cell populations, prognostic factors and therapeutic implications","volume":"9","author":"Joseph","year":"2019","journal-title":"Front Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-016-1945-z","article-title":"Intratumoral Th2 predisposition combines with an increased Th1 functional phenotype in clinical response to intravesical BCG in bladder cancer","volume":"66","author":"Pichler","year":"2017","journal-title":"Cancer Immunol Immunother"},{"key":"B15","doi-asserted-by":"publisher","first-page":"189","DOI":"10.31083\/j.fbl2808189","article-title":"RBP7 regulated by EBF1 affects th2 cells and the oocyte meiosis pathway in bone metastases of bladder urothelial carcinoma","volume":"28","author":"Liu","year":"2023","journal-title":"Front Biosci (Landmark Ed)"},{"key":"B16","doi-asserted-by":"publisher","first-page":"16","DOI":"10.25259\/Cytojournal_166_2024","article-title":"Ailanthone inhibits bladder cancer tumor and cell proliferation, epithelial-mesenchymal transition, and activation of the Janus kinase\/signal transducer and activator of transcription 3 signaling pathway","volume":"22","author":"Li","year":"2025","journal-title":"Cytojournal"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2012.05.001","article-title":"Novel thalidomide analogues from diamines inhibit pro-inflammatory cytokine production and CD80 expression while enhancing IL-10","volume":"66","author":"Mazzoccoli","year":"2012","journal-title":"BioMed Pharmacother"},{"key":"B18","doi-asserted-by":"publisher","first-page":"101351","DOI":"10.1016\/j.trim.2020.101351","article-title":"Soluble CD83 inhibits acute rejection by up regulating TGF-\u03b2 and IDO secretion in rat liver transplantation","volume":"64","author":"Xiong","year":"2021","journal-title":"Transpl Immunol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"120635","DOI":"10.1016\/j.lfs.2022.120635","article-title":"Articulatin B chain induced dendritic cells maturation and driven type I T helper cells and cytotoxic T cells activation","volume":"302","author":"Lu","year":"2022","journal-title":"Life Sci"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.7150\/ijms.61510","article-title":"Therapeutic antitumor efficacy of cancer stem cell-derived DRibble vaccine on colorectal carcinoma","volume":"18","author":"Fu","year":"2021","journal-title":"Int J Med Sci"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1089\/dna.2021.0936","article-title":"Gastric cancer cell-derived kynurenines hyperactive regulatory T cells to promote chemoresistance via the IL-10\/STAT3\/BCL2 signaling pathway","volume":"41","author":"Wu","year":"2022","journal-title":"DNA Cell Biol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"107706","DOI":"10.1016\/j.actatropica.2025.107706","article-title":"et al: Trichinella spiralis excretory-secretory protein alleviates autoimmune thyroiditis by modulating Th17\/Treg balance via the STAT3\/STAT5 pathway","volume":"268","author":"Xu","year":"2025","journal-title":"Acta Trop"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/s41585-019-0226-y","article-title":"The multifaceted immune regulation of bladder cancer","volume":"16","author":"Schneider","year":"2019","journal-title":"Nat Rev Urol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.32604\/or.2024.056282","article-title":"Exploring the utility of a NGS multigene panel to predict BCG response in patients with non-muscle invasive bladder cancer","volume":"33","author":"Francesca","year":"2025","journal-title":"Oncol Res"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-018-0009-3","article-title":"An early history of T cell-mediated cytotoxicity","volume":"18","author":"Golstein","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/s41580-020-00324-8","article-title":"Ferroptosis: mechanisms, biology and role in disease","volume":"22","author":"Jiang","year":"2021","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"23523735251322017","DOI":"10.1177\/23523735251322017","article-title":"Single-cell RNA sequencing and spatial transcriptome analysis in bladder cancer: Current status and future perspectives","volume":"11","author":"Yoshihara","year":"2025","journal-title":"Bladder Cancer"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1522582","article-title":"Spatially-resolved analyses of muscle invasive bladder cancer microenvironment unveil a distinct fibroblast cluster associated with prognosis","volume":"15","author":"Feng","year":"2024","journal-title":"Front Immunol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/s41392-024-01947-5","article-title":"Tertiary lymphoid structures in diseases: immune mechanisms and therapeutic advances","volume":"9","author":"Zhao","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"B30","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/s41392-024-01979-x","article-title":"Cold and hot tumors: from molecular mechanisms to targeted therapy","volume":"9","author":"Wu","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"B31","doi-asserted-by":"publisher","first-page":"e4","DOI":"10.4110\/in.2020.20.e4","article-title":"Regulatory T cells in tumor microenvironment and approach for anticancer immunotherapy","volume":"20","author":"Kim","year":"2020","journal-title":"Immune Netw"},{"key":"B32","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s12967-023-03949-3","article-title":"Tumor-associated macrophages and Tregs influence and represent immune cell infiltration of muscle-invasive bladder cancer and predict prognosis","volume":"21","author":"Koll","year":"2023","journal-title":"J Transl Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000978","article-title":"Intratumoral TIGIT(+) CD8(+) T-cell infiltration determines poor prognosis and immune evasion in patients with muscle-invasive bladder cancer","volume":"8","author":"Liu","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B34","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s13045-023-01499-1","article-title":"Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy","volume":"16","author":"Cai","year":"2023","journal-title":"J Hematol Oncol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"e1134412","DOI":"10.1080\/2162402X.2015.1134412","article-title":"The ratio of CD8 to Treg tumor-infiltrating lymphocytes is associated with response to cisplatin-based neoadjuvant chemotherapy in patients with muscle invasive urothelial carcinoma of the bladder","volume":"5","author":"Baras","year":"2016","journal-title":"Oncoimmunology"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1527428","article-title":"Editorial: Immune cell exhaustion: new challenges and opportunities in cancer therapy","volume":"15","author":"Chi","year":"2024","journal-title":"Front Immunol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2016.367","article-title":"CXCL2\/MIF-CXCR2 signaling promotes the recruitment of myeloid-derived suppressor cells and is correlated with prognosis in bladder cancer","volume":"36","author":"Zhang","year":"2017","journal-title":"Oncogene"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1080\/08830185.2021.1938566","article-title":"MDSCs interactions with other immune cells and their role in maternal-fetal tolerance","volume":"41","author":"Zhang","year":"2022","journal-title":"Int Rev Immunol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"187","DOI":"10.37349\/etat","article-title":"Novel therapeutic strategies targeting myeloid-derived suppressor cell immunosuppressive mechanisms for cancer treatment","volume":"5","author":"Jou","year":"2024","journal-title":"Explor Target Antitumor Ther"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2021.737364","article-title":"Myeloid-derived suppressor cells in trypanosoma cruzi infection","volume":"11","author":"Fresno","year":"2021","journal-title":"Front Cell Infect Microbiol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3390\/cells10102655","article-title":"Regulation of T cells in cancer by nitric oxide","volume":"10","author":"Navasardyan","year":"2021","journal-title":"Cells"},{"key":"B42","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s12935-025-03676-3","article-title":"Mcl-1 downregulation enhances BCG treatment efficacy in bladder cancer by promoting macrophage polarization","volume":"25","author":"Tan","year":"2025","journal-title":"Cancer Cell Int"},{"key":"B43","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00262-019-02443-4","article-title":"Immunotherapy: Mechanisms of immune evasion in bladder cancer","volume":"69","author":"Crispen","year":"2020","journal-title":"Cancer Immunol Immunother"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1172\/JCI89717","article-title":"ILC2-modulated T cell-to-MDSC balance is associated with bladder cancer recurrence","volume":"127","author":"Chevalier","year":"2017","journal-title":"J Clin Invest"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1080\/01635581.2025.2480309","article-title":"Emodin decreases tumor-associated macrophages accumulation and suppresses bladder cancer development by inhibiting CXCL1 secretion from cancer-associated fibroblasts","volume":"77","author":"Yu","year":"2025","journal-title":"Nutr Cancer"},{"key":"B46","doi-asserted-by":"publisher","first-page":"114119","DOI":"10.1016\/j.intimp.2025.114119","article-title":"Histone lactylation regulates PRKN-Mediated mitophagy to promote M2 Macrophage polarization in bladder cancer","volume":"148","author":"Deng","year":"2025","journal-title":"Int Immunopharmacol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"175630","DOI":"10.1016\/j.ejphar.2023.175630","article-title":"Mollugin ameliorates murine allergic airway inflammation by inhibiting Th2 response and M2 macrophage activation","volume":"946","author":"Li","year":"2023","journal-title":"Eur J Pharmacol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1007\/s12672-025-03137-3","article-title":"Nicotine and tar-multiple targets synergize to alter the immune micro-environment to induce prostate cancer","volume":"16","author":"Zeng","year":"2025","journal-title":"Discov Oncol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1578146","article-title":"Advancements in bladder cancer immunotherapy: a focus on intravesical approaches","volume":"16","author":"Tang","year":"2025","journal-title":"Front Pharmacol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.18632\/aging.202150","article-title":"A TP53-based immune prognostic model for muscle-invasive bladder cancer","volume":"13","author":"Li","year":"2020","journal-title":"Aging (Albany NY)"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.23736\/S0031-0808.24.05102-4","article-title":"Research progress of ICIS in the treatment of bladder cancer","author":"Wang","year":"2024","journal-title":"Panminerva Med"},{"key":"B52","doi-asserted-by":"publisher","first-page":"2267301","DOI":"10.1080\/21645515.2023.2267301","article-title":"Knowledge-map analysis of bladder cancer immunotherapy","volume":"19","author":"Lv","year":"2023","journal-title":"Hum Vaccin Immunother"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2021.02.004","article-title":"Diagnosis and staging of bladder cancer","volume":"35","author":"Ahmadi","year":"2021","journal-title":"Hematol Oncol Clin North Am"},{"key":"B54","doi-asserted-by":"publisher","first-page":"14374","DOI":"10.3390\/ijms241814374","article-title":"Molecular Markers for Bladder Cancer Screening: An Insight into Bladder Cancer and FDA-Approved Biomarkers","volume":"24","author":"Flores Monar","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B55","doi-asserted-by":"publisher","first-page":"S8","DOI":"10.4111\/icu.2020.61.S1.S8","article-title":"urology c: Advances in urinary biomarker discovery in urological research","volume":"61","author":"Kim","year":"2020","journal-title":"Investig Clin Urol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"39","DOI":"10.3390\/diagnostics10010039","article-title":"Biomarkers for bladder cancer diagnosis and surveillance: a comprehensive review","volume":"10","author":"Batista","year":"2020","journal-title":"Diagnostics (Basel)"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-022-04253-3","article-title":"Urinary biomarkers for bladder cancer diagnosis and NMIBC follow-up: a systematic review","volume":"41","author":"Soorojebally","year":"2023","journal-title":"World J Urol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2016.06.001","article-title":"Replacing cystoscopy by urine markers in the follow-up of patients with low-risk non-muscle-invasive bladder cancer?-An International Bladder Cancer Network project","volume":"34","author":"Schmitz-Dr\u00e4ger","year":"2016","journal-title":"Urol Oncol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.18521","article-title":"The prognostic and diagnostic value of circulating tumor cells in bladder cancer and upper tract urothelial carcinoma: a meta-analysis of 30 published studies","volume":"8","author":"Zhang","year":"2017","journal-title":"Oncotarget"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2024.04.034","article-title":"Advancements in precision nanomedicine design targeting the anoikis-platelet interface of circulating tumor cells","volume":"14","author":"Tang","year":"2024","journal-title":"Acta Pharm Sin B"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(01)65185-1","article-title":"Evolution and clinical significance of the T cell proliferative and cytokine response directed against the fibronectin binding antigen 85 complex of bacillus Calmette-Guerin during intravesical treatment of superficial bladder cancer","volume":"157","author":"Zlotta","year":"1997","journal-title":"J Urol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.0c01627","article-title":"TLR2 agonistic small molecules: detailed structure-activity relationship, applications, and future prospects","volume":"64","author":"Kaur","year":"2021","journal-title":"J Med Chem"},{"key":"B63","doi-asserted-by":"publisher","first-page":"113240","DOI":"10.1016\/j.celrep.2023.113240","article-title":"Toll-like receptor 4 and CD11b expressed on microglia coordinate eradication of Candida albicans cerebral mycosis","volume":"42","author":"Wu","year":"2023","journal-title":"Cell Rep"},{"key":"B64","doi-asserted-by":"publisher","first-page":"110393","DOI":"10.1016\/j.biopha.2020.110393","article-title":"Mechanisms of BCG in the treatment of bladder cancer-current understanding and the prospect","volume":"129","author":"Han","year":"2020","journal-title":"BioMed Pharmacother"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1038\/s41585-018-0055-4","article-title":"Mechanisms of BCG immunotherapy and its outlook for bladder cancer","volume":"15","author":"Pettenati","year":"2018","journal-title":"Nat Rev Urol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2017.10.003","article-title":"Predicting response to intravesical bacillus Calmette-Gu\u00e9rin immunotherapy: are we there yet? A systematic review","volume":"73","author":"Kamat","year":"2018","journal-title":"Eur Urol"},{"key":"B67","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12935-020-01362-0","article-title":"Immune-related long non-coding RNA signature identified prognosis and immunotherapeutic efficiency in bladder cancer (BLCA)","volume":"20","author":"Cao","year":"2020","journal-title":"Cancer Cell Int"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2018.06.045","article-title":"Conventional and PD-L1-expressing regulatory T cells are enriched during BCG therapy and may limit its efficacy","volume":"74","author":"Chevalier","year":"2018","journal-title":"Eur Urol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01460","article-title":"In vitro evidence of human immune responsiveness shows the improved potential of a recombinant BCG strain for bladder cancer treatment","volume":"10","author":"Rodriguez","year":"2019","journal-title":"Front Immunol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2018.10.010","article-title":"Building on a solid foundation: enhancing bacillus Calmette-Guerin therapy","volume":"4","author":"Rentsch","year":"2018","journal-title":"Eur Urol Focus"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2022.04.013","article-title":"Final results of neoadjuvant atezolizumab in cisplatin-ineligible patients with muscle-invasive urothelial cancer of the bladder","volume":"82","author":"Szabados","year":"2022","journal-title":"Eur Urol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10214837","article-title":"KIFC1 is associated with basal type, cisplatin resistance, PD-L1 expression and poor prognosis in bladder cancer","volume":"10","author":"Sekino","year":"2021","journal-title":"J Clin Med"},{"key":"B73","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/s11864-019-0609-6","article-title":"Treatment approaches for cisplatin-ineligible patients with invasive bladder cancer","volume":"20","author":"Einstein","year":"2019","journal-title":"Curr Treat Options Oncol"},{"key":"B74","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.ctrv.2019.04.002","article-title":"Management of metastatic bladder cancer","volume":"76","author":"Nadal","year":"2019","journal-title":"Cancer Treat Rev"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1007\/s12254-018-0396-y","article-title":"PD-1 and PD-L1 inhibitors after platinum-based chemotherapy or in first-line therapy in cisplatin-ineligible patients: Dramatic improvement of prognosis and overall survival after decades of hopelessness in patients with metastatic urothelial cancer","volume":"11","author":"Resch","year":"2018","journal-title":"Memo"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-1457","article-title":"Probody therapeutics: an emerging class of therapies designed to enhance on-target effects with reduced off-tumor toxicity for use in immuno-oncology","volume":"26","author":"Autio","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B77","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.1200\/JCO.2019.37.15_suppl.2513","article-title":"CX-072, a PD-L1 Probody therapeutic, as monotherapy in patients with advanced solid tumors: Preliminary results of PROCLAIM-CX-072","volume":"37","author":"Naing","year":"2019","journal-title":"J Clin Oncol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-018-3518-7","article-title":"Pharmacology: Role of immunotherapy in bladder cancer: past, present and future","volume":"81","author":"Butt","year":"2018","journal-title":"Cancer Chemother Pharmacol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N Engl J Med"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)33297-X","article-title":"Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial","volume":"391","author":"Powles","year":"2018","journal-title":"Lancet"},{"key":"B81","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S1470-2045(23)00540-5","article-title":"Atezolizumab plus chemotherapy versus placebo plus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis results from a randomised, controlled, phase 3 study","volume":"25","author":"Grande","year":"2024","journal-title":"Lancet Oncol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2034442","article-title":"Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma","volume":"384","author":"Bajorin","year":"2021","journal-title":"N Engl J Med"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30065-7","article-title":"Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial","volume":"18","author":"Sharma","year":"2017","journal-title":"Lancet Oncol"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.4524","article-title":"Nivolumab monotherapy in patients with advanced platinum-resistant urothelial carcinoma: Efficacy and safety update from CheckMate 275","volume":"26","author":"Siefker-Radtke","year":"2019","journal-title":"Am Soc Clin Oncol"},{"key":"B85","doi-asserted-by":"publisher","first-page":"e172411","DOI":"10.1001\/jamaoncol.2017.2411","article-title":"Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: updated results from a phase 1\/2 open-label study","volume":"3","author":"Powles","year":"2017","journal-title":"JAMA Oncol"},{"key":"B86","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S1470-2045(17)30900-2","article-title":"Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial","volume":"19","author":"Patel","year":"2018","journal-title":"Lancet Oncol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14681","article-title":"Tislelizumab in Asian patients with previously treated locally advanced or metastatic urothelial carcinoma","volume":"112","author":"Ye","year":"2021","journal-title":"Cancer Sci"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00538","article-title":"Nivolumab alone and with ipilimumab in previously treated metastatic urothelial carcinoma: CheckMate 032 nivolumab 1 mg\/kg plus ipilimumab 3 mg\/kg expansion cohort results","volume":"37","author":"Sharma","year":"2019","journal-title":"J Clin Oncol"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33328","article-title":"Results of a multicenter, phase 2 study of nivolumab and ipilimumab for patients with advanced rare genitourinary Malignancies","volume":"127","author":"McGregor","year":"2021","journal-title":"Cancer"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30616-2","article-title":"First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study","volume":"18","author":"Balar","year":"2017","journal-title":"Lancet Oncol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02887","article-title":"Enfortumab vedotin with or without pembrolizumab in cisplatin-ineligible patients with previously untreated locally advanced or metastatic urothelial cancer","volume":"41","author":"O\u2019Donnell","year":"2023","journal-title":"J Clin Oncol"},{"key":"B92","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S0140-6736(16)32455-2","article-title":"Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial","volume":"389","author":"Balar","year":"2017","journal-title":"Lancet"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx518","article-title":"Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: post-progression outcomes from the phase II IMvigor210 study","volume":"28","author":"Necchi","year":"2017","journal-title":"Ann Oncol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00152-2","article-title":"Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial","volume":"22","author":"Powles","year":"2021","journal-title":"Lancet Oncol"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.6_suppl.435","article-title":"Post-hoc analysis of long-term outcomes in patients with CR, PR, or SD to pembrolizumab (pembro) or platinum-based chemotherapy (chemo) as 1L therapy for advanced urothelial carcinoma (UC) in KEYNOTE-361","volume":"39","author":"Loriot","year":"2021","journal-title":"Am Soc Clin Oncol"},{"key":"B96","doi-asserted-by":"publisher","first-page":"e341","DOI":"10.1016\/S1470-2045(18)30433-9","article-title":"EMA restricts use of anti-PD-1 drugs for bladder cancer","volume":"19","author":"Gourd","year":"2018","journal-title":"Lancet Oncol"},{"key":"B97","doi-asserted-by":"publisher","first-page":"10501","DOI":"10.1038\/ncomms10501","article-title":"Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints","volume":"7","author":"Koyama","year":"2016","journal-title":"Nat Commun"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30541-6","article-title":"Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial","volume":"21","author":"Powles","year":"2020","journal-title":"Lancet Oncol"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30458-9","article-title":"Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a\/b trial","volume":"20","author":"Herbst","year":"2019","journal-title":"Lancet Oncol"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02303","article-title":"FORT-1: phase II\/III study of rogaratinib versus chemotherapy in patients with locally advanced or metastatic urothelial carcinoma selected based on FGFR1\/3 mRNA expression","volume":"41","author":"Sternberg","year":"2023","journal-title":"J Clin Oncol"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2021.04.012","article-title":"Metastatic urothelial carcinoma","volume":"39","author":"Knowles","year":"2021","journal-title":"Cancer Cell"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2002788","article-title":"Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma","volume":"383","author":"Powles","year":"2020","journal-title":"N Engl J Med"},{"key":"B103","doi-asserted-by":"publisher","first-page":"738","DOI":"10.3390\/cancers12030738","article-title":"Review of indications of FDA-approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence","volume":"12","author":"Vaddepally","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.03091","article-title":"Randomized double-blind phase II study of maintenance pembrolizumab versus placebo after first-line chemotherapy in patients with metastatic urothelial cancer","volume":"38","author":"Galsky","year":"2020","journal-title":"J Clin Oncol"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.01148","article-title":"Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01): an open-label, single-arm, phase II study","volume":"36","author":"Necchi","year":"2018","journal-title":"J Clin Oncol"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.09.011","article-title":"Does the administration of preoperative pembrolizumab lead to sustained remission post-cystectomy? First survival outcomes from the PURE-01 study(\u2606)","volume":"31","author":"Bandini","year":"2020","journal-title":"Ann Oncol"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0628-7","article-title":"Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial","volume":"25","author":"Powles","year":"2019","journal-title":"Nat Med"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2020.11.010","article-title":"Toxicity and surgical complication rates of neoadjuvant atezolizumab in patients with muscle-invasive bladder cancer undergoing radical cystectomy: updated safety results from the ABACUS trial","volume":"4","author":"Szabados","year":"2021","journal-title":"Eur Urol Oncol"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1001\/jamapediatrics.2021.0630","article-title":"Trends in geographic and temporal distribution of US children with multisystem inflammatory syndrome during the COVID-19 pandemic","volume":"175","author":"Belay","year":"2021","journal-title":"JAMA Pediatr"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-1085-z","article-title":"Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial","volume":"26","author":"van Dijk","year":"2020","journal-title":"Nat Med"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-1086-y","article-title":"Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma","volume":"26","author":"Gao","year":"2020","journal-title":"Nat Med"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2022.02.003","article-title":"Health-related quality of life with adjuvant nivolumab after radical resection for high-risk muscle-invasive urothelial carcinoma: results from the phase 3 CheckMate 274 trial","volume":"5","author":"Witjes","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.11.012","article-title":"Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up\u2606","volume":"33","author":"Powles","year":"2022","journal-title":"Ann Oncol"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00004-8","article-title":"Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial","volume":"22","author":"Bellmunt","year":"2021","journal-title":"Lancet Oncol"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02762","article-title":"Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients","volume":"41","author":"Stein","year":"2023","journal-title":"J Clin Oncol"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2019.02.017","article-title":"Midterm health-related quality of life after radical cystectomy: A propensity score-matched analysis","volume":"6","author":"Kretschmer","year":"2020","journal-title":"Eur Urol Focus"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2015.03.015","article-title":"Radiotherapy complements immune checkpoint blockade","volume":"27","author":"Ngiow","year":"2015","journal-title":"Cancer Cell"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-14-1258","article-title":"Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade","volume":"74","author":"Dovedi","year":"2014","journal-title":"Cancer Res"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.4505","article-title":"Phase II trial of durvalumab plus tremelimumab with concurrent radiotherapy (RT) in patients (pts) with localized muscle invasive bladder cancer (MIBC) treated with a selective bladder preservation approach: IMMUNOPRESERVE-SOGUG trial","volume":"39","author":"Garcia del Muro","year":"2021","journal-title":"J Clin Oncol"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.4504","article-title":"Pembrolizumab (pembro) in combination with gemcitabine (Gem) and concurrent hypofractionated radiation therapy (RT) as bladder sparing treatment for muscle-invasive urothelial cancer of the bladder (MIBC): A multicenter phase 2 trial","volume":"39","author":"Balar","year":"2021","journal-title":"J Clin Oncol"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.4503","article-title":"Phase 2 trial of gemcitabine, cisplatin, plus nivolumab with selective bladder sparing in patients with muscle-invasive bladder cancer (MIBC): HCRN GU 16-257","volume":"39","author":"Galsky","year":"2021","journal-title":"J Clin Oncol"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2013.12.034","article-title":"Words of wisdom. Re: Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Gu\u00e9rin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance","volume":"65","author":"Solsona","year":"2014","journal-title":"Eur Urol"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.32604\/or.2025.061812","article-title":"Intradermal priming to intravesical Bacillus Calmette-Gu\u00e9rin in non-muscle invasive bladder cancer: A translational research and phase I clinical trial","volume":"33","author":"Saboya","year":"2025","journal-title":"Oncol Res"},{"key":"B124","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41590-023-01700-0","article-title":"BCG vaccination stimulates integrated organ immunity by feedback of the adaptive immune response to imprint prolonged innate antiviral resistance","volume":"25","author":"Lee","year":"2024","journal-title":"Nat Immunol"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-1920","article-title":"Adaptive immune resistance to intravesical BCG in non-muscle invasive bladder cancer: implications for prospective BCG-unresponsive trials","volume":"26","author":"Kates","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B126","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s00345-024-05392-5","article-title":"PD-L1 expression in high-risk non-muscle invasive bladder cancer is not a biomarker of response to BCG","volume":"43","author":"de Jong","year":"2025","journal-title":"World J Urol"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-018-6498-2","article-title":"Clinical role of programmed cell death-1 expression in patients with non-muscle-invasive bladder cancer recurring after initial bacillus calmette-gu\u00e9rin therapy","volume":"25","author":"Fukumoto","year":"2018","journal-title":"Ann Surg Oncol"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00147-9","article-title":"Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study","volume":"22","author":"Balar","year":"2021","journal-title":"Lancet Oncol"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.4541","article-title":"Phase II trial of atezolizumab in BCG-unresponsive non-muscle invasive bladder cancer: SWOG S1605 (NCT02844816)","volume":"39","author":"Black","year":"2021","journal-title":"J Clin Oncol"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.5022","article-title":"Phase II trial of atezolizumab in BCG-unresponsive non-muscle invasive bladder cancer: SWOG S1605 (NCT02844816)","volume":"84","author":"Black","year":"2020","journal-title":"Am Soc Clin Oncol"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.915171","article-title":"CAR-T cells in the treatment of urologic neoplasms: present and future","volume":"12","author":"Zhang","year":"2022","journal-title":"Front Oncol"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.782448","article-title":"Epigenetic priming of bladder cancer cells with decitabine increases cytotoxicity of human EGFR and CD44v6 CAR engineered T-cells","volume":"12","author":"Grunewald","year":"2021","journal-title":"Front Immunol"},{"key":"B133","doi-asserted-by":"publisher","first-page":"e1248","DOI":"10.1002\/cti2.1248","article-title":"Patient-derived organoids of bladder cancer recapitulate antigen expression profiles and serve as a personal evaluation model for CAR-T cells in vitro","volume":"10","author":"Yu","year":"2021","journal-title":"Clin Transl Immunol"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-019-0329-2","article-title":"The therapeutic landscape for cells engineered with chimeric antigen receptors","volume":"38","author":"MacKay","year":"2020","journal-title":"Nat Biotechnol"},{"key":"B135","doi-asserted-by":"publisher","first-page":"e2400156","DOI":"10.1002\/advs.202400156","article-title":"Novel CAR-T cells specifically targeting SIA-CIgG demonstrate effective antitumor efficacy in bladder cancer","volume":"11","author":"Ding","year":"2024","journal-title":"Adv Sci (Weinh)"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1609871\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T05:20:05Z","timestamp":1755580805000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1609871\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,19]]},"references-count":135,"alternative-id":["10.3389\/fimmu.2025.1609871"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1609871","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,19]]},"article-number":"1609871"}}